Also, the company said that it was unable to collect some debts, resulting into an increase in credit loss and interest. This is the second time in a row that Cipla is announcing disappointing results after listing on the Uganda Securities Exchange in September 2018.
The company has not performed up to the investors' expectations.
Drug maker Cipla Quality Chemicals Industries Limited has
issued a profit warning, informing shareholders and people who intend to buy
its shares that it will record a loss for period between April to September,
2019. The company says this is due to low sales of medicines realized in
this period and increased pressure from competitors, which has reduced its
Also, the company said that it was unable to collect some
debts, resulting into an increase in credit loss and interest. This
is the second time in a row that Cipla is announcing disappointing results after
listing on the Uganda Securities Exchange in September 2018.
In March, the company announced an 85% fall in profits for a
year between March 2018 to March 2019, dropping from 44.6 billion Shillings to Shillings
6.8 billion respectively. People who bought shares in the company are yet to earn a
dividend – little wonder that there is no appetite for the company’s stock and
more people want to sell.
The share price fell from the initial public offering price
of Shillings 265 a share to Shillings 128 on Tuesday morning. In March 2019, the company tried to calm fears of
shareholders about the company's dismal performance, saying it "had
secured the first ever tender award by the USA President's Malaria Initiative
(PMI) for WHO prequalified antimalarial to an African based Manufacturer".
"That is one example of how we are constantly in search
of alternative revenue streams and product opportunities to future proof our
business," the company said. It all looks like things haven’t worked its favor. Investors
will have to wait longer before they can earn anything.
which was established in 2005 manufactures Anti-retroviral (ARV),
artemisinin-based combination therapies (ACTs) and Hepatitis medicines to treat
HIV/AIDS, Malaria and Hepatitis. The company is majority owned by India's third-largest drug